Verastem (VSTM) Q3 2026 Earnings Call Transcript
Verastem (VSTM) reported Q3 2026 earnings, highlighting FDA acceptance of its new blister pack NDA with a February 2027 PDUFA date. The company shared positive clinical data for VS-7375 in pancreatic, colorectal, and lung cancers, raising $250M to fund operations into 2028. Q3 revenue for AVMAPKI FAKZYNJA CO-PACK was $24M, with plans to expand its use in approved indications. CEO Dan Patterson will step down at the end of 2026, succeeded by Michael Bailey.
How this was made

The 30-second read
Why it matters
The FDA priority‑review acceptance is the most material new development, potentially driving share price higher.
Market read
Regulatory progress for a late‑stage oncology asset can move the stock and influence peer valuations.
What to watch
The upcoming Phase III trial timeline and competitive landscape in KRAS‑mutated cancers.
Background
Verastem discussed its Q3 2026 earnings call, highlighting clinical data, a $250 M capital raise, and an executive transition.
Ticker impact
FDA accepted Verastem's new blister pack NDA for priority review with a PDUFA date in February 2027.
potential upside as the market prices in the priority review status
A priority review signals a faster path to market, which is material for a biotech with an unmet‑need program.
Market effects
Other KRAS‑targeted oncology firms may see increased attention as the field gains momentum.
US biotech sector could benefit from the regulatory milestone.
Limited to biotech investors; no broad market effect.
Counterpoint
If the FDA later requests additional data, the initial upside could be short‑lived.
Key entities
- companyVerastem
US‑listed biotech developing KRAS‑targeted therapies.
- personMichael Bailey
Incoming CEO, former AVEO/LG Chem executive.

